University of Alabama at Birmingham

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).

1,160 total trials 216 currently recruiting 723 completed early-phase tilt top decile by trial count

University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.

University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 62/100

723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,160 total, page 19 of 24

COMPLETED NA

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966

COMPLETED NA

Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study

NCT01512264

TERMINATED

The Bottle Study: Infant Weight Gain During Use of Novel Versus Typical Infant Feeding Bottles

NCT01526018

COMPLETED

MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder.

NCT01547481

COMPLETED Phase 2

Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

NCT01361048

COMPLETED

The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery

NCT01464840

COMPLETED

Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))

NCT01880983

COMPLETED Phase 1

Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial

NCT01242462

COMPLETED

Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room

NCT01661478

COMPLETED

The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain

NCT00885976

COMPLETED Phase 2

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

NCT01438307

COMPLETED NA

Blue Wavelength Light-blocking Glasses in ADHD-Insomnia

NCT01557595

TERMINATED Early Phase 1

Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting

NCT01661517

COMPLETED

Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function

NCT01431027

COMPLETED

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

NCT01546714

COMPLETED NA

Re-feeding Gastric Residuals in Preterm Infants

NCT01420263

TERMINATED Phase 1

Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

NCT01404702

COMPLETED NA

Withdrawal Exposure With Withdrawal Regulation Training for Smoking Cessation

NCT02192762

COMPLETED Phase 4

Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient

NCT01277250

TERMINATED Phase 1

Psychosocial Benefits of Exercise in Endometrial Cancer Survivors

NCT01401829

COMPLETED

Development of Post Traumatic Stress Disorder After Natural Disaster

NCT01661452

COMPLETED Early Phase 1

Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces

NCT01494844

COMPLETED

Bone Mineral Density in HIV+ Patients

NCT01378494

TERMINATED Phase 4

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

NCT01349114

COMPLETED Phase 4

Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension

NCT01330108

COMPLETED NA

The Alabama NSAIDs Patient Safety Survey, Phase II: Reducing Disparities in Risk Awareness and Communication

NCT01352832

COMPLETED NA

Performance of MicroTextured Dental Implants

NCT01821417

COMPLETED

A Case Control Study of Women With Multiple Sexual Partners

NCT01578915

TERMINATED

Routine Clinical Screening for Substance Use Disorders in the Emergency Room Setting

NCT01661465

COMPLETED NA

Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia

NCT01363258

COMPLETED NA

Impact of Food Additives on Phosphorus Metabolism

NCT01394146

COMPLETED Early Phase 1

A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients

NCT01770626

COMPLETED NA

African American Children, Glycemic Control, and Type 2 Diabetes

NCT01325987

COMPLETED NA

Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)

NCT01410643

COMPLETED Phase 2

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

NCT01307891

TERMINATED Phase 4

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926

COMPLETED NA

Comparison of Three Toothpastes for the Prevention and Reduction of White Spot Lesions

NCT03440996

COMPLETED Phase 4

An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine

NCT01578941

COMPLETED Phase 2

Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer

NCT00827164

COMPLETED NA

Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse

NCT01431040

COMPLETED NA

Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns

NCT01197807

COMPLETED NA

A Study to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments to Promote Tissue Healing

NCT01822223

COMPLETED Phase 1

Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)

NCT01252797

COMPLETED NA

Medifast 5 & 1 Plan

NCT01211301

COMPLETED Early Phase 1

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

NCT01247298

COMPLETED Phase 4

Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids

NCT01378689

COMPLETED

Efficacy of Enhancing Low Vision Mobility Thru Visual Training in Virtual World

NCT02310880

COMPLETED NA

Physical Activity, Fatigue, Sleep, and Inflammation

NCT01147367

COMPLETED NA

Journey to Better Health

NCT02938312

COMPLETED NA

Effect of Deep Brain Stimulation (DBS) on Sleep Architecture in Patients With Movement Disorders

NCT01169324

← Previous Page 19 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 129
Phase 2 130
Phase 3 25
Phase 4 72

What is open in the University of Alabama at Birmingham pipeline

216 recruiting of 1,160 indexed (19% open); 723 completed (62%).

Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Alabama at Birmingham: open-pipeline peers nationwide

Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share University of Alabama at BirminghamNYU Langone HealthWake Forest University Health SciencesEmory UniversityNorthwestern UniversityUniversity of MinnesotaMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,160 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Alabama at Birmingham page

1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.

  • 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.